Cochlear Ltd on Wednesday dramatically pared back its full-year earnings expectation and warned of multiple headwinds weighing on its business, sending shares tumbling to their lowest level in a decade.
The hearing implant specialist now expects FY26 underlying net profit of A$290 million-A$330 million, down from the prior guidance range of A$435 million-A$460 million. Management said softer trading conditions across developed markets have materially weakened near-term performance.
Sydney-listed shares fell 38.2% to A$103.87 by 01:15 GMT, marking the lowest closing-level since April 2016 and reflecting investor reassessment of near-term growth and margin prospects.
On sales, Cochlear trimmed its outlook for second-half growth to 2%–6% in constant currency. The company attributed the moderation to subdued demand for cochlear implants, with adults and seniors particularly affected.
Operational and market dynamics cited as contributing factors include constrained hospital capacity, fewer referrals from hearing aid channels and weaker consumer sentiment in key markets such as the United States. These factors, the company said, have reduced the pace of procedures and orders coming through the system.
Beyond demand-side pressures, Cochlear flagged elevated geopolitical risk in the Middle East tied to ongoing conflict. The company warned this could lead to order cancellations, delivery delays and identified a potential A$10 million exposure from receivables provisioning related to the region.
Management also signalled margin pressure ahead as lower production volumes are expected to weigh on unit economics. In addition, a stronger Australian dollar is projected to reduce reported earnings by about A$25 million after tax, further compressing profitability versus prior expectations.
The constellation of weaker demand, hospital and referral constraints, regional geopolitical uncertainty and currency impacts underpinned the decision to revise guidance and sparked the sharp market reaction.
Contextual note - The company has provided specific point estimates and ranges for profit, sales growth and potential regional receivable provisioning. The market reaction was immediate and substantial, as reflected in the share price movement to levels not seen since April 2016.